[Leptin level in azoospermic patients and its clinical value]

Area of Science:

• Reproductive Endocrinology
• Andrology
• Biomarker Discovery

Context:

• Azoospermia, characterized by the absence of sperm in ejaculate, is a significant cause of male infertility.
• Distinguishing between obstructive azoospermia (OA) and non-obstructive azoospermia (NOA) is crucial for guiding treatment strategies.
• Leptin, a hormone involved in energy balance, has been implicated in reproductive function, but its role in azoospermia requires further elucidation.

Purpose:

• To quantify seminal plasma leptin (SPL) and serum leptin (SL) levels in men with azoospermia.
• To evaluate the diagnostic utility of SPL and SL, individually and in combination with follicle-stimulating hormone (FSH), for differentiating OA from NOA.

Summary:

• This study analyzed SPL, SL, and FSH levels in 45 OA patients, 41 NOA patients, and 30 controls.
• NOA patients exhibited significantly higher levels of FSH, SL, and SPL compared to controls and OA patients.
• Receiver operating characteristic (ROC) curve analysis demonstrated that the combination of SPL, SL, and FSH provided the highest accuracy (0.953) in differentiating OA from NOA, with sensitivity and specificity of 0.878 and 0.902, respectively.

Impact:

• The findings suggest that SPL and SL are valuable biomarkers for azoospermia diagnosis.
• The combined assessment of SPL, SL, and FSH significantly enhances the accuracy of differentiating between obstructive and non-obstructive azoospermia.
• This integrated biomarker approach could lead to improved diagnostic protocols and personalized treatment plans for infertile men.